Syndax Announces Participation at Two Upcoming Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Syndax Pharmaceuticals, a clinical stage biopharmaceutical firm, will participate in two virtual investor conferences. The first event is a panel at the Cowen 41st Annual Health Care Conference on March 3, 2021, at 11:40 a.m. ET. The second event is a fireside chat at the Barclays Global Healthcare Conference on March 9, 2021, at 3:35 p.m. ET. Interested parties can access a live webcast of the Barclays presentation through the Company's website, where a replay will also be available. Syndax is developing innovative cancer therapies, including SNDX-5613, axatilimab, and entinostat.
Details
News Market Reaction – SNDX
The recorded move for SNDX in the trading session of this news was +10.27%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Feb. 24, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in two upcoming virtual investor conferences:
- A panel at the Cowen 41st Annual Health Care Conference at 11:40 a.m. ET on Wednesday, March 3, 2021.
- A fireside chat at the Barclays Global Healthcare Conference at 3:35 p.m. ET on Tuesday, March 9, 2021.
A live webcast of the Barclays presentation can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay of the event will also be available for a limited time.
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company's pipeline includes SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, and entinostat, a class I HDAC inhibitor. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn.
Syndax Contacts
Investor Contact
Melissa Forst
Argot Partners
melissa@argotpartners.com
Tel 212.600.1902
Media Contact
Ted Held
ted.held@gcihealth.com
Tel 212.798.9842
SNDX-G
View original content:http://www.prnewswire.com/news-releases/syndax-announces-participation-at-two-upcoming-investor-conferences-301234357.html
SOURCE Syndax Pharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.